ALK and lung cancer: The anaplastic lymphoma kinase (ALK) inhibitor ceritinib was found to be capable of modulating the protein-trafficking and degradation-related process of autophagy after the quantitative analysis of five lung cancer cell lines in response to more than 50 drugs.77